Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med 2013;369:134-44. DOI: 10.1056/NEJMoa1305133

Supplemental Tables Table of Contents

Table number	Short title/description	Pages
Table S1	RECIST 1.1 and irRC response criteria	2
Table S2	Drug-related adverse events in ≥1% of population	3-7
Table S3	Adverse events regardless of causality in ≥ 5% of population	8-11
Table S4	Geometric mean (GM) and coefficient of variation (CV%) for lambrolizumab serum concentrations	12
Table S5	Summary of Exposure to lambrolizumab	13

Table S1. RECIST 1.1 and irRC response criteria, which provides the definitions of the criteria used to determine objective tumor response for target and non-target lesions.

	Evaluation of target and non-target* lesions by RECIST 1.1[1]	Evaluation of lesions by irRC[†2]
Complete Response (CR)	• Disappearance of all target lesions. • Normalization of tumor marker level for non-target lesions. • Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm • Confirmation is required at least 4 weeks later[‡]	• (irCR) Complete disappearance of all tumor lesions (whether measureable or not, and no new lesions) two consecutive observations not less than 4 weeks apart
Partial Response (PR)	• At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters • Confirmation is required at least 4 weeks later[‡]	• (irPR) ≥ 50% decrease in tumor burden compared with baseline in two observations at least 4 weeks apart
Progressive Disease (PD)	• At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). • In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression) • Unequivocal progression (see comments below) of existing non-target lesions. • The appearance of one or more new lesions[‡] is also considered progression	• (irPD) At least 25% increase in tumor burden compared with nadir (minimum recorded tumor burden at any single time point) in two consecutive observations at least 4 weeks apart
Stable Disease (SD)	• Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study	• 50% decrease in tumor burden compared with baseline cannot be established nor 25% increase compared with nadir

*While some non-target lesions may actually be measurable, they need not be measured and instead should be assessed only qualitatively at the time points specified in the protocol.

[†]New measurable lesions (i.e., ≥ 5 x 5 mm) are incorporated into tumor burden and do not automatically trigger PD. New non-measurable lesions, i.e., <5 x 5mm do not define progression but preclude irCR. Non-index lesions contribute to defining irCR (complete disappearance required).

[‡]New lesions: The appearance of new malignant lesions denotes disease progression. There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion should be unequivocal. That is, it should not be attributable to differences in scanning technique, change in imaging modality or findings thought to represent something other than tumor.

[‡]Confirmation of response is required in non-randomized trials where response is the primary endpoint.

1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47.
2. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research, 2009 Dec 1;15(23):7412-20.

Table S2. Drug-related adverse events that occurred in at least 1% of the All Treated Patient Population

	10 mg/kg Q2W		10 mg/kg Q3W		2.0 mg/kg Q3W		Total	
Drug related adverse events	**n (%)**	**grade 3-4**	**n (%)**	**grade 3-4**	**n (%)**	**grade 3-4**	**n (%)**	**grade 3-4**
Patients in population	57		56		22		135	
with one or more adverse events	52 (91.2)	13 (22.8)	41 (73.2)	2 (3.6)	14 (63.6)	2 (9.1)	107 (79.3)	17 (12.6)
Blood And Lymphatic System Disorders								
Anemia	4 (7.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (3.0)	0 (0.0)
Leukopenia	1 (1.8)	0 (0.0)	1 (1.8)	0 (0.0)	1 (4.5)	0 (0.0)	3 (2.2)	0 (0.0)
Thrombocytopenia	1 (1.8)	0 (0.0)	1 (1.8)	0 (0.0)	2 (9.1)	0 (0.0)	4 (3.0)	0 (0.0)
Endocrine Disorders								
Hypothyroidism	9 (15.8)	1 (1.8)	1 (1.8)	0 (0.0)	1 (4.5)	0 (0.0)	11 (8.1)	1 (0.7)
Eye Disorders								
Dry Eye	4 (7.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (3.0)	0 (0.0)
Uveitis	0 (0.0)	0 (0.0)	2 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Visual Impairment	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.5)	0 (0.0)	2 (1.5)	0 (0.0)
Gastrointestinal Disorders								
Abdominal Discomfort	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Abdominal Distension	3 (5.3)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.2)	1 (0.7)
Abdominal Pain	6 (10.5)	1 (1.8)	0 (0.0)	0 (0.0)	1 (4.5)	0 (0.0)	7 (5.2)	1 (0.7)
Constipation	2 (3.5)	0 (0.0)	2 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	4 (3.0)	0 (0.0)

Diarrhea	12 (21.1)	1 (1.8)	9 (16.1)	0 (0.0)	6 (27.3)	0 (0.0)	27 (20.0)	1 (0.7)
Dry Mouth	3 (5.3)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	4 (3.0)	0 (0.0)
Nausea	7 (12.3)	0 (0.0)	4 (7.1)	0 (0.0)	2 (9.1)	0 (0.0)	13 (9.6)	0 (0.0)
Vomiting	3 (5.3)	1 (1.8)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	4 (3.0)	1 (0.7)
General Disorders								
Asthenia	11 (19.3)	0 (0.0)	2 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	13 (9.6)	0 (0.0)
Chills	6 (10.5)	0 (0.0)	2 (3.6)	0 (0.0)	1 (4.5)	0 (0.0)	9 (6.7)	0 (0.0)
Fatigue	26 (45.6)	2 (3.5)	13 (23.2)	0 (0.0)	2 (9.1)	0 (0.0)	41 (30.4)	1 (0.7)
Edema Peripheral	3 (5.3)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	4 (3.0)	0 (0.0)
Night Sweats	3 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.2)	0 (0.0)
Pyrexia	7 (12.3)	0 (0.0)	3 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	10 (7.4)	0 (0.0)
Infections								
Diverticulitis	1 (1.8)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Influenza	3 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.2)	0 (0.0)
Laboratory abnormalities								
ALT Increased	6 (10.5)	0 (0.0)	5 (8.9)	0 (0.0)	0 (0.0)	0 (0.0)	11 (8.1)	0 (0.0)
AST Increased	7 (12.3)	0 (0.0)	5 (8.9)	2 (3.6)	1 (4.5)	0 (0.0)	13 (9.6)	2 (1.5)
Blood Alkaline Phosphatase Increased	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Blood Cholesterol Increased	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Blood Creatinine Increased	3 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.2)	0 (0.0)
Platelet Count Decreased	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)

Transaminases Increased	1 (1.8)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Weight Decreased	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Metabolism And Nutrition Disorders								
Decreased Appetite	5 (8.8)	1 (1.8)	0 (0.0)	0 (0.0)	1 (4.5)	0 (0.0)	6 (4.4)	1 (0.7)
Dehydration	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Hyperglycemia	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.5)	0 (0.0)	2 (1.5)	0 (0.0)
Musculoskeletal And Connective Tissue Disorders								
Arthralgia	12 (21.1)	0 (0.0)	7 (12.5)	0 (0.0)	1 (4.5)	0 (0.0)	20 (14.8)	0 (0.0)
Arthritis	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Back Pain	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Muscle Spasms	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	1 (4.5)	0 (0.0)	2 (1.5)	0 (0.0)
Muscular Weakness	1 (1.8)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Myalgia	12 (21.1)	0 (0.0)	3 (5.4)	0 (0.0)	1 (4.5)	0 (0.0)	16 (11.9)	0 (0.0)
Neck Pain	1 (1.8)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Pain In Extremity	1 (1.8)	0 (0.0)	1 (1.8)	0 (0.0)	1 (4.5)	0 (0.0)	3 (2.2)	0 (0.0)
Nervous System Disorders								
Balance Disorder	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Dizziness	2 (3.5)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.2)	0 (0.0)
Dysgeusia	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	1 (4.5)	0 (0.0)	2 (1.5)	0 (0.0)
Headache	10 (17.5	0 (0.0)	3 (5.4)	0 (0.0)	1 (4.5)	0 (0.0)	14 (10.4)	0 (0.0)
Neuropathy Peripheral	3 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.2)	0 (0.0)

Psychiatric Disorders								
Confusion	1 (1.8)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Renal And Urinary Disorders								
Renal failure	2 (3.5)	2 (3.5)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.2)	2 (1.5)
Respiratory Disorders								
Cough	6 (10.5)	0 (0.0)	3 (5.4)	0 (0.0)	2 (9.10	0 (0.0)	11 (8.1)	0 (0.0)
Dyspnea	5 (8.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.5)	0 (0.0)	6 (4.4)	0 (0.0)
Nasal Congestion	0 (0.0)	0 (0.0)	2 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Pneumonitis	4 (7.0)	0 (0.0)	2 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	6 (4.4)	0 (0.0)
Productive Cough	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Skin And Subcutaneous Tissue Disorders								
Eczema	3 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.2)	0 (0.0)
Erythema	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.5)	0 (0.0)	2 (1.5)	0 (0.0)
Hair Color Changes	2 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Pruritus	15 (26.3)	0 (0.0)	9 (16.1)	0 (0.0)	4 (18.2)	1 (4.5)	28 (20.7)	1 (0.7)
Rash	15 (26.3)	2 (3.5)	10 (17.9)	0 (0.0)	3 (13.6)	1 (4.5)	28 (20.7)	3 (2.2)
Rash Maculo-Papular	1 (1.8)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.5)	0 (0.0)
Vitiligo	7 (12.3)	0 (0.0)	4 (7.1)	0 (0.0)	1 (4.5)	0 (0.0)	12 (8.9)	0 (0.0)
Vascular Disorders								
Hot Flush	2 (3.5)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.2)	0 (0.0)

ALT: alanine aminotransferase; AST: aspartate aminotransferase

Table S3. Adverse events regardless of causality that occurred in at least 5% of the All Treated Patient Population

	10 mg/kg Q2W n (%)		10 mg/kg Q3W n (%)		2.0 mg/kg Q3W n (%)		Total n (%)	
	All grades	Grade 3-4	All grades	Grade 3-4	All grades	Grade 3-4	All grades	Grade 3-4
Patients in population	57		56		22		135	
with one or more adverse events	55 (96.5)	24 (42.1)	55 (98.2)	16 (28.6)	22 (100)	7 (31.8)	132 (97.8)	47 (34.8)
Blood And Lymphatic System Disorders								
Anemia	14 (24.6)	3 (5.3)	6 (10.7)	1 (1.8)	2 (9.1)	0 (0.0)	22 (16.3)	4 (3.0)
Endocrine Disorders								
Hypothyroidism	10 (17.5)	1 (1.8)	1 (1.8)	0 (0.0)	1 (4.5)	0 (0.0)	12 (8.9)	1 (0.7)
Eye Disorders								
Dry Eye	4 (7.0)	0 (0.0)	3 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	7 (5.2)	0 (0.0)
Gastrointestinal Disorders								
Abdominal Pain	10 (17.5)	2 (3.5)	6 (10.7)	1 (1.8)	4 (18.2)	0 (0.0)	20 (14.8)	3 (2.2)
Abdominal Pain Upper	6 (10.5)	0 (0.0)	2 (3.6)	0 (0.0)	1 (4.5)	0 (0.0)	9 (6.7)	0 (0.0)
Constipation	7 (12.3)	0 (0.0)	12 (21.4)	0 (0.0)	2 (9.1)	0 (0.0)	21 (15.6)	0 (0.0)
Diarrhea	19 (33.3)	1 (1.8)	13 (23.2)	0 (0.0)	8 (36.4)	0 (0.0)	40 (29.6)	1 (0.7)
Dry Mouth	5 (8.8)	0 (0.0)	3 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	8 (5.9)	0 (0.0)

Nausea	16 (28.1)	0 (0.0)	11 (19.6)	0 (0.0)	6 (27.3)	1 (4.5)	33 (24.4)	1 (0.7)
Vomiting	9 (15.8)	1 (1.8)	7 (12.5)	0 (0.0)	4 (18.2)	1 (4.5)	20 (14.8)	2 (1.5)
General Disorders And Administration Site Conditions								
Asthenia	12 (21.1)	0 (0.0)	2 (3.6)	0 (0.0)	1 (4.5)	0 (0.0)	15 (11.1)	0 (0.0)
Chills	9 (15.8)	0 (0.0)	4 (7.1)	0 (0.0)	1 (4.5)	0 (0.0)	14 (10.4)	0 (0.0)
Fatigue	28 (49.1)	3 (5.3)	17 (30.4)	0 (0.0)	5 (22.7)	0 (0.0)	50 (37.0)	3 (2.2)
Night Sweats	5 (8.8)	0 (0.0)	2 (3.6)	0 (0.0)	1 (4.5)	0 (0.0)	8 (5.9)	0 (0.0)
Edema Peripheral	8 (14.0)	0 (0.0)	3 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	11 (8.1)	0 (0.0)
Pyrexia	15 (26.3)	0 (0.0)	4 (7.1)	0 (0.0)	1 (4.5)	0 (0.0)	20 (14.8)	0 (0.0)
Infections And Infestations								
Nasopharyngitis	3 (5.3)	0 (0.0)	2 (3.6)	0 (0.0)	2 (9.1)	0 (0.0)	7 (5.2)	0 (0.0)
Sinusitis	5 (8.8)	0 (0.0)	2 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	7 (5.2)	0 (0.0)
Upper Respiratory Tract Infection	6 (10.5)	0 (0.0)	1 (1.8)	0 (0.0)	4 (18.2)	0 (0.0)	11 (8.1)	0 (0.0)
Urinary Tract Infection	7 (12.3)	1 (1.8)	2 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	9 (6.7)	1 (0.7)
Investigations								
ALT Increased	10 (17.5)	1 (1.8)	5 (8.9)	0 (0.0)	1 (4.5)	0 (0.0)	16 (11.9)	1 (0.7)
AST Increased	12 (21.1)	1 (1.8)	7 (12.5)	2 (3.6)	2 (9.1)	0 (0.0)	21 (15.6)	3 (2.2)
Blood Creatinine Increased	6 (10.5)	0 (0.0)	2 (3.6)	0 (0.0)	1 (4.5)	0 (0.0)	9 (6.7)	0 (0.0)
Weight Decreased	5 (8.8)	0 (0.0)	3 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	8 (5.9)	0 (0.0)

Metabolism And Nutrition Disorders								
Decreased Appetite	10 (17.5)	1 (1.8)	9 (16.1)	1 (1.8)	2 (9.1)	0 (0.0)	21 (15.6)	2 (1.5)
Hyperglycemia	6 (10.5)	0 (0.0)	1 (1.8)	0 (0.0)	1 (4.5)	0 (0.0)	8 (5.9)	0 (0.0)
Hypertriglyceridemia	3 (5.3)	1 (1.8)	4 (7.1)	1 (1.8)	0 (0.0)	0 (0.0)	7 (5.2)	2 (1.5)
Hypoalbuminemia	7 (12.3)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7 (5.2)	1 (0.7)
Hypokalemia	7 (12.3)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	8 (5.9)	0 (0.0)
Hyponatremia	6 (10.5)	3 (5.3)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	7 (5.2)	3 (2.2)
Musculoskeletal And Connective Tissue Disorders								
Arthralgia	14 (24.6)	0 (0.0)	10 (17.9)	0 (0.0)	2 (9.1)	0 (0.0)	26 (19.3)	0 (0.0)
Back Pain	4 (7.0)	0 (0.0)	3 (5.4)	0 (0.0)	1 (4.5)	0 (0.0)	8 (5.9)	0 (0.0)
Musculoskeletal Pain	5 (8.8)	1 (1.8)	5 (8.9)	0 (0.0)	0 (0.0)	0 (0.0)	10 (7.4)	1 (0.7)
Myalgia	13 (22.8)	0 (0.0)	3 (5.4)	0 (0.0)	1 (4.5)	0 (0.0)	17 (12.6)	0 (0.0)
Pain In Extremity	7 (12.3)	0 (0.0)	3 (5.4)	0 (0.0)	2 (9.1)	0 (0.0)	12 (8.9)	0 (0.0)
Nervous System Disorders								
Dizziness	5 (8.8)	0 (0.0)	6 (10.7)	0 (0.0)	2 (9.1)	0 (0.0)	13 (9.6)	0 (0.0)
Headache	16 (28.1)	0 (0.0)	11 (19.6)	2 (3.6)	4 (18.2)	1 (4.5)	31 (23.0)	3 (2.2)
Psychiatric Disorders								
Insomnia	5 (8.8)	0 (0.0)	5 (8.9)	0 (0.0)	1 (4.5)	0 (0.0)	11 (8.1)	0 (0.0)
Respiratory, Thoracic And Mediastinal Disorders								

Cough	19 (33.3)	0 (0.0)	15 (26.8)	0 (0.0)	4 (18.2)	0 (0.0)	38 (28.1)	0 (0.0)
Dyspnea	10 (17.5)	0 (0.0)	8 (14.3)	2 (3.6)	1 (4.5)	0 (0.0)	19 (14.1)	2 (1.5)
Nasal Congestion	3 (5.3)	0 (0.0)	3 (5.4)	0 (0.0)	1 (4.5)	0 (0.0)	7 (5.2)	0 (0.0)
Oropharyngeal Pain	4 (7.0)	0 (0.0)	3 (5.4)	0 (0.0)	1 (4.5)	0 (0.0)	8 (5.9)	0 (0.0)
Skin And Subcutaneous Tissue Disorders								
Pruritus	18 (31.6)	0 (0.0)	10 (17.9)	0 (0.0)	4 (18.2)	1 (4.5)	32 (23.7)	1 (0.7)
Rash	16 (28.1)	2 (3.5)	14 (25.0)	0 (0.0)	3 (13.6)	1 (4.5)	33 (24.4)	3 (2.2)
Vitiligo	7 (12.3)	0 (0.0)	4 (7.1)	0 (0.0)	2 (9.1)	0 (0.0)	13 (9.6)	0 (0.0)
Vascular Disorders								
Hypertension	2 (3.5)	1 (1.8)	4 (7.1)	0 (0.0)	1 (4.5)	0 (0.0)	7 (5.2)	1 (0.7)

ALT: alanine aminotransferase; AST: aspartate aminotransferase

Every patient is counted a single time for each applicable row and column. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Table S4. Geometric mean (GM) and coefficient of variation (CV%) for lambrolizumab serum concentrations predose and postdose following administration of single and multiple 2 or 10 mg/kg IV doses with 2 or 3 weeks dosing intervals

		Pre-dose			Post-dose		
			GM			GM	
Dosing	Cycle	N	µg/mL	CV%	N	µg/mL	CV%
10 mg/kg Q2W	1	56	n.a.	n.a.	54	213	31
	3	50	85.3	60	48	298	40
	7	41	142	52			
2 mg/kg Q3W	1	75	n.a.	n.a.	77	44.2	50
	3	16	11.5	66	16	52.2	37
	5	28	21.7	67			
10 mg/kg Q3W	1	84	n.a.	n.a.	84	244	43
	3	30	72.8	79	27	283	61
	5	30	118	66			

n.a.=not available

Table S5. Summary of Exposure to lambrolizumab, All Treated Patient Population

	10 mg/kg Q2W	10 mg/kg Q3W	2 mg/kg Q3W	Total
	N=57	N=56	N=22	N=135
Study Days On-Therapy (weeks)				
Median	40.1	20.6	18.1	23.1
Range	1.0 to 53.3	1.0 to 48.1	1.0 to 39.1	1.0 to 53.3
Number of Administrations				
Median	12	6.5	7	8
Range	1 to 26	1 to 18	1 to 14	1 to 26